2022.

• Jun.23.2022 Management / Finance

  Announcement on Disposal of Treasury Shares as Restricted Stock-based Remuneration

• Jun.07.2022 R & D

  Three-Year Data from Phase 3 CheckMate -9LA Trial Demonstrate Long-Term, Durable Survival Outcomes of Opdivo (nivolumab) Plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer

• Jun.07.2022 R & D

  Landmark Five-Year Data from Phase 3 CheckMate -227 Trial Demonstrate Long-Term, Durable Survival Outcomes with Opdivo (nivolumab) Plus Yervoy (ipilimumab) in First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer

• May.30.2022 R & D

  U.S. Food and Drug Administration Approves Two Opdivo® (nivolumab)-Based Regimens as First-Line Treatments for Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma

• May.26.2022 R & D

  Two Combination Treatments of Opdivo + Yervoy and Opdivo + Chemotherapy Approved in Japan for First-line Treatment of Unresectable Advanced or Recurrent Esophageal Cancer

• May.19.2022 R & D

  Bristol Myers Squibb Provides Update on CheckMate -901 Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) as First-Line Treatment for Patients with Unresectable or Metastatic Urothelial Carcinoma

• May.18.2022 R & D

  Opdivo® Intravenous Infusion Approved for the Treatment of Previously Untreated or Advanced Renal Cell Carcinoma in Combination with Cabozantinib in Taiwan

• May.11.2022 Management / Finance

  Announcement on Financial Results for FY2021

• May.11.2022 Management / Finance

  Notice regarding Differences in the Non-consolidated Financial Results between the Fiscal Year Ended March 31, 2022 and the Previous Fiscal Year

• May.11.2022 Corporate

  Notice regarding Partial Amendments to the Articles of Incorporation

• May.11.2022 Corporate

  Announcement on the Revision of Remuneration System for Members of the Board of Directors

• Apr.28.2022 Management / Finance

  Ono Announces Completion of Cancellation of Treasury Stock

• Apr.25.2022 R & D

  ONO Submits Supplemental Application for Approval of Opdivo® (Nivolumab) in Combination with Chemotherapy to Expand its Use as Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer in Japan

• Apr.19.2022 Licensing

  Ono Enters into Collaboration Agreement with Domain Therapeutics and Université de Montréal for GPCR-Targeted Drug Discovery

• Apr.13.2022 R & D

  FDA Lifts Partial Clinical Hold on MDS and AML Magrolimab Studies

• Apr.12.2022 R & D

  Opdivo® Intravenous Infusion Approved in Taiwan for the Adjuvant Treatment of Urothelial Carcinoma

• Apr.06.2022 R & D

  Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) as First-Line Treatment for Patients with Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma with Tumor Cell PD-L1 Expression ≥ 1%

• Apr.06.2022 R & D

  Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) with Chemotherapy as First-Line Treatment for Patients with Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma with Tumor Cell PD-L1 Expression ≥ 1%

• Apr.06.2022 R & D

  Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Radically Resected, High-Risk Muscle-Invasive Urothelial Carcinoma with Tumor Cell PD-L1 Expression ≥1%

• Apr.06.2022 Corporate

  Announcement on Changes of the Board of Directors and Corporate Officers

• Apr.06.2022 Management / Finance

  Notice regarding Partial Amendments to the Retirement of Treasury Shares

• Apr.01.2022 Corporate

  Notice concerning the Establishment of Ono Pharma UD Co., Ltd.

• Apr.01.2022 Corporate

  Initiation of Providing "Fukusapo", an Adverse Drug Reaction Management Supporting Tool for Patients Receiving Treatment with Immune Checkpoint Inhibitors

• Mar.31.2022 Licensing

  ONO Enters into a Development and License Agreement with Numab

• Mar.30.2022 Licensing

  ONO Enters into Collaboration Agreement with Iktos

• Mar.30.2022 R & D

  European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer

• Mar.28.2022 R & D

  ONO Receives Supplemental Approval of Opdivo® (Nivolumab) for Adjuvant Treatment of Urothelial Carcinoma in Japan

• Mar.22.2022 R & D

  U.S. Food and Drug Administration Approves First LAG-3-Blocking Antibody Combination, Opdualag™ (nivolumab and relatlimab-rmbw), as Treatment for Patients with Unresectable or Metastatic Melanoma

• Mar.18.2022 Corporate

  Notice regarding the Reorganization of Research Bases

• Mar.15.2022 Sustainability

  Humanitarian Assistance in Ukraine and its Surrounding Areas

• Mar.07.2022 R & D

  U.S. Food and Drug Administration Approves Opdivo® (nivolumab) with Chemotherapy as Neoadjuvant Treatment for Certain Adult Patients with Resectable Non-Small Cell Lung Cancer

• Mar.01.2022 R & D

  U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Opdivo (nivolumab) Plus Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer

• Feb.28.2022 Corporate

  Filing of Patent Infringement Suit against AstraZeneca K.K.

• Feb.28.2022 R & D

  Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) plus Yervoy (ipilimumab) for First-line Treatment of Patients with Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma with Tumor Cell PD-L1 Expression ≥ 1%

• Feb.28.2022 R & D

  Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) plus Chemotherapy for First-Line Treatment of Patients with Unresectable, Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma with Tumor Cell PD-L1 Expression ≥ 1%

• Feb.28.2022 R & D

  Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Radically Resected, High-Risk Muscle-Invasive Urothelial Carcinoma with Tumor Cell PD-L1 Expression ≥1%

• Feb.28.2022 Management / Finance

  Ono Announces Status and Completion of Acquisition of Own Shares

• Feb.24.2022 Corporate

  Notice regarding Collaboration between Ono and Maruha Nichiro in the Field of Health Foods

• Feb.21.2022 R & D

  Velexbru® Tablet 80 mg, a BTK inhibitor, Approved in Taiwan for the Treatment of Recurrent or Refractory B-cell Primary Central Nervous System Lymphoma

• Feb.15.2022 R & D

  Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Continued Survival Benefits with Over Two Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma

• Feb.15.2022 R & D

  Opdivo® Intravenous Infusion Approved in South Korea for Two Adjuvant Treatments and Three Combination Treatments

• Feb.03.2022 R & D

  ONO and Bristol Myers Squibb Sign Outsourcing Agreement with PRiME-R on Clinical Research of Opdivo® in Patients with Gastric Cancer, utilizing CyberOncology® in Japan

• Feb.01.2022 Management / Finance

  Ono Announces Status of Acquisition of Own Shares

• Jan.31.2022 Management / Finance

  Announcement on Financial Results for FY2021 3Q

• Jan.28.2022 R & D

  Gilead Announces Partial Clinical Hold for Studies Evaluating Magrolimab in Combination with Azacitidine

• Jan.25.2022 R & D

  Opdivo® Intravenous Infusion Approved for the First-line Treatment of Metastatic or Recurrent Non-squamous Non-small Cell Lung Cancer in Combination with Bevacizumab and Chemotherapy in Taiwan

• Jan.17.2022 Licensing

  Ono Expands Drug Discovery Collaboration with Neurimmune AG in the Field of Neurodegenerative Diseases

• Jan.05.2022 R & D

  Opdivo® Intravenous Infusion Approved for the Adjuvant Treatment of Esophageal Cancer or Gastroesophageal Junction Cancer in Taiwan

• Jan.05.2022 Management / Finance

  Ono Announces Status of Acquisition of Own Shares